Investigating barriers in HIV-testing oncology patients. The IBITOP study: phase I.

Background : Since the advent of combined antiretroviral therapy (ART), the incidence of non-AIDS-defining cancers (non-ADCs) among HIV-positive patients is rising. We previously described HIV testing rates of 0.1%. Phase II of the IBITOP study is now underway to explore barriers to HIV screening among oncologists and patients following the updated national HIV testing guidelines which recommend testing in non-ADC patients undergoing chemotherapy. (Published: 2 November 2014) Citation : Abstracts of the HIV Drug Therapy Glasgow Congress 2014 Merz L et al. Journal of the International AIDS Society 2014, 17(Suppl 3) :19622 http://www.jiasociety.org/index.php/jias/article/view/19622 | http://dx.doi.org/10.7448/IAS.17.4.19622